Galderma Celebrates 20th Global Anniversary of Restylane®
Restylane® Marks Heritage Milestone and Announces Innovative Syringe
Galderma, a global leader focused on medical solutions in skin health, is proud to celebrate the significant milestone of the 20th global anniversary of the Restylane® portfolio of products1. One of the world’s most studied wrinkle fillers2, Restylane has been used in more than 65 countries worldwide with over 28 million treatments administered globally2.
“The launch of the Restylane dermal filler in Europe in 1996 and in the United States in 2003 helped to change the aesthetic landscape. It quickly became a household name, and sparked a shift in how many of my patients approached facial aging,” said Chicago-based physician Steve Dayan. “This anniversary not only celebrates 20 years of being a great option for men and women who want natural-looking results, but also serves as a proof point for how well-placed my trust is in the long track record of safety and efficacy of Restylane products in my practice.”
Restylane(R) has been used for over 20 years globally with over 28 million treatments worldwide.
After more than two decades of research, the complete line of Restylane fillers – including Restylane®, Restylane-L®, Restylane® Lyft with Lidocaine and Restylane® Silk – have well-defined safety profiles3,4,5,6. With six major product approvals and four different indications, the Restylane family of products continues to deliver effective and proven aesthetic solutions to healthcare professionals and their patients allowing specialists to customize a treatment plan that’s right for each individual3,4,5,6.
Innovative Syringe Delivers Enhanced Ergonomics and Safety
Building on the heritage of the milestones in the last 20 years, Galderma is committed to continuing its leadership role of Restylane innovation in the future.
Today, Galderma is proud to introduce a new, enhanced syringe for Restylane and Restylane Lyft. The new syringe will be available to practitioners during the second half of 2016. Key attributes of this new introduction include:
- A design focused on greater working comfort and enhanced ergonomics for the injector
- A state of the art design boasting sturdy construction and upgraded safety measures with a tamper-proof seal delivering heightened anti-counterfeiting protection for patient and clinician security
- Updated Restylane packaging designed to simplify product identification and selection
“All of us at Galderma are inspired by this significant milestone for Restylane,” said Kelly Huang, PhD, Vice President and General Manager, Aesthetic & Corrective Business Unit, Galderma, U.S. “The combination of the proven safety history backed by over 28 million treatments globally and a continual pipeline of innovation, such as our enhanced syringe introduction for key Restylane products, is a strong foundation for the Restylane brands to continue to support the goals of healthcare professionals and patients now and in the future.”
Dr. West Talks Mom Genes Campaign, Prejuvenation and More!
To schedule your consultation with Dr. West, call 301-986-9378 (WEST) today!
Galderma and Sharon Stone Put Fillers to the Test
About Dr. West
Dr. Tina B. West, founder of the West Institute, has served as a consultant and injectable trainer for Allergan and Galderma, training other physicians in advanced treatment techniques using Restylane, Perlane, Scupltra and Dysport as well as Botox.
Dr. West is a board-certified Dermatologist and leading expert in cosmetic dermatology, laser surgery and body contouring procedures.
Dr. West participated in the original phase III FDA clinical trials for the approval of Botox.
The West Institute
5530 Wisconsin Avenue #925
Chevy Chase, MD20815